Article
Medicine, General & Internal
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Summary: This study aimed to investigate whether giving pembrolizumab both before and after surgery would improve event-free survival in patients with resectable stage III or IV melanoma. Results showed that patients who received pembrolizumab both before and after surgery had significantly longer event-free survival. Overall rating: 9 out of 10.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This trial evaluated the safety and efficacy of ipatasertib in combination with different chemotherapy regimens for metastatic triple-negative breast cancer (mTNBC). The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and the overall response rates and progression-free survival varied among the different treatment arms. Further study is needed to better understand the role of AKT inhibition in the treatment of TNBCs.
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This study evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple-negative breast cancer (mTNBC). The primary endpoints were safety and recommended phase II dose (RP2D), while secondary endpoints included progression-free survival (PFS), response rate, and overall survival. The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and further research is needed to understand the role of AKT inhibition in the treatment of TNBC.
Article
Oncology
Marina C. Garassino, Shirish Gadgeel, Giovanna Speranza, Enriqueta Felip, Emilio Esteban, Manuel Domine, Maximilian J. Hochmair, Steven F. Powell, Helge G. Bischoff, Nir Peled, Francesco Grossi, Ross R. Jennens, Martin Reck, Rina Hui, Edward B. Garon, Takayasu Kurata, Jhanelle E. Gray, Paul Schwarzenberger, Erin Jensen, M. Catherine Pietanza, Delvys Rodriguez-Abreu
Summary: This study presents the 5-year outcomes of the KEYNOTE-189 study, which included previously untreated metastatic nonsquamous non-small-cell lung cancer patients. The results show that treatment with pembrolizumab plus pemetrexed-platinum significantly improves overall survival and progression-free survival compared to placebo plus pemetrexed-platinum. These data continue to support pembrolizumab plus pemetrexed-platinum as a standard of care for previously untreated metastatic non-small-cell lung cancer patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Dorota Kwapisz
Summary: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis and limited treatment options, but it shows higher immunogenicity, tumor-infiltrating lymphocytes (TILs) enrichment, and programmed cell death ligand 1 (PD-L1) expression which make it more suitable for immune checkpoint blockade therapy. Patients with PD-L1-positive TNBC subgroup may benefit the most from immune checkpoint inhibitor (ICI) treatment, and ICI given as first-line treatment in advanced TNBC shows better results than in later lines of treatment. Exciting results have been seen with pembrolizumab in early-stage TNBC, indicating potential approval in (neo)adjuvant settings in the near future.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Assuntina G. Sacco, Ruifeng Chen, Francis P. Worden, Deborah J. L. Wong, Douglas Adkins, Paul Swiecicki, Wanxing Chai-Ho, Peter Oppelt, Debanjali Ghosh, Julie Bykowski, Alfredo Molinolo, Emily Pittman, M. Valeria Estrada, Kathryn Gold, Gregory Daniels, Scott M. Lippman, Amanda Natsuhara, Karen Messer, Ezra E. W. Cohen
Summary: The study aimed to evaluate the anti-tumour activity of PD-1 blockade with EGFR inhibition in recurrent or metastatic head and neck squamous cell carcinoma. Results showed a 45% overall response rate at 6 months for the combination of pembrolizumab and cetuximab.
Article
Oncology
Brian G. Topp, Madhav Channavazzala, Kapil Mayawala, Dinesh P. De Alwis, Eric Rubin, Alexandra Snyder, Jedd D. Wolchok, Antoni Ribas
Summary: Pembrolizumab demonstrates meaningful efficacy in a subset of patients treated beyond RECIST v1.1 progression, with some patients showing reduction in lesion diameter and others exhibiting stable target lesion.
Article
Oncology
Nikolaj Frost, Annalen Bleckmann, Frank Griesinger, Christian Grohe, Melanie Janning, Jens Kollmeier, Niels Reinmuth, Martin Sebastian, Michael Thomas, Martin Reck
Summary: Pemetrexed-free regimens may have better outcomes compared to pemetrexed-containing regimens in TTF-1 negative NSCLC/ADC patients. The ANTELOPE trial aims to compare atezolizumab, carboplatin, and nab-paclitaxel with pembrolizumab, cis-/carboplatin, and pemetrexed in this specific subset of patients.
CLINICAL LUNG CANCER
(2023)
Review
Biochemistry & Molecular Biology
Sri Harsha Tella, Anuhya Kommalapati, Amit Mahipal, Zhaohui Jin
Summary: Hepatocellular carcinoma (HCC) is a common and aggressive malignancy. Treatment options depend on disease stage, liver function, and clinical evaluation. Combination of immunotherapy and anti-VEGF therapy has shown better efficacy in first-line treatment of advanced HCC.
Review
Biochemistry & Molecular Biology
Michael C. Stark, Anna M. Joubert, Michelle H. Visagie
Summary: Immune checkpoint inhibitors (ICIs) are effective immunotherapy agents that can overcome the immunosuppressive effects exerted by tumorigenic cells, specifically targeting the PD-1/PD-L1 immune checkpoint. However, the high cost of ICIs like pembrolizumab and nivolumab limits their accessibility in LMICs. Therefore, developing cost-effective biomanufacturing platforms is crucial for expanding access to these therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell Biology
Thomas S. Uldrick, Scott Adams, Remi Fromentin, Michael Roche, Steven P. Fling, Priscila H. Goncalves, Kathryn Lurain, Ramya Ramaswami, Chia-Ching Jackie Wang, Robert J. Gorelick, Jorden L. Welker, Liz O'Donoghue, Harleen Choudhary, Jeffrey D. Lifson, Thomas A. Rasmussen, Ajantha Rhodes, Carolin Tumpach, Robert Yarchoan, Frank Maldarelli, Martin A. Cheever, Rafick Sekaly, Nicolas Chomont, Steven G. Deeks, Sharon R. Lewin
Summary: This study aimed to evaluate the effect of anti-PD-1 antibodies on reversing HIV latency. The results showed that administration of anti-PD-1 antibodies increased the levels of unspliced HIV RNA and the RNA:DNA ratio in CD4(+) T cells. There was also an increase in the frequency of CD4(+) T cells with inducible virus. The study suggests that combining anti-PD-1 with other interventions may help reduce the HIV reservoir.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Review
Medicine, General & Internal
Jianxin Chen, Junhui Wang, Hui Xu
Summary: The study found no statistical difference in PFS or OS among atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in ES-SCLC patients. However, durvalumab showed superiority in ORR compared to atezolizumab, but also had significantly higher risk of immune-related AEs.
Article
Oncology
Tom van den Ende, Nicolien C. de Clercq, Mark I. van Berge Henegouwen, Suzanne S. Gisbertz, E. D. Geijsen, R. H. A. Verhoeven, Sybren L. Meijer, Sandor Schokker, M. P. G. Dings, Jacques J. G. H. M. Bergman, Nadia Haj Mohammad, Jelle P. Ruurda, Richard van Hillegersberg, Stella Mook, Max Nieuwdorp, Tanja D. de Gruijl, Tanya T. D. Soeratram, Bauke Ylstra, Nicole C. T. van Grieken, Maarten F. Bijlsma, Maarten C. C. M. Hulshof, H. W. M. van Laarhoven
Summary: The study demonstrated the feasibility of combining nCRT with PD-L1 inhibition for patients with rEAC. Most patients proceeded to surgery after receiving all cycles of atezolizumab, and some experienced immune-related adverse events. Exploratory biomarker analysis suggested the potential of neoadjuvant immunotherapy in certain patient subgroups.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Mehul Gupta, Igor Stukalin, Daniel Meyers, Sid Goutam, Daniel Y. C. Heng, Tina Cheng, Jose Monzon, Vishal Navani
Summary: This study evaluated the treatment-free survival (TFS) outcomes for patients with advanced melanoma receiving first-line immune checkpoint inhibitor (ICI) therapy. The findings suggest that patients treated with combination nivolumab-ipilimumab had better outcomes in terms of time and survival compared to those treated with anti-PD-1 monotherapy alone.
Article
Medicine, General & Internal
Niharika B. Mettu, Fang-Shu Ou, Tyler J. Zemla, Thorvardur R. Halfdanarson, Heinz-Josef Lenz, Rimini A. Breakstone, Patrick M. Boland, Oxana Crysler, Christina Wu, Andrew B. Nixon, Emily Bolch, Donna Niedzwiecki, Alicia Elsing, Herbert Hurwitz, Marwan G. Fakih, Tanios Bekaii-Saab
Summary: Cotargeting vascular endothelial growth factor and programmed cell death 1 or programmed cell death ligand 1 may produce anticancer activity in refractory metastatic colorectal cancer (mCRC). This study aimed to evaluate the improvement of progression-free survival (PFS) by adding atezolizumab in patients with refractory mCRC and to explore the efficacy in patients with microsatellite-stable (MSS) disease and liver metastasis. The results showed limited clinical benefit of adding atezolizumab to capecitabine and bevacizumab therapy. Patients with MSS and proficient mismatch repair tumors and those without liver metastasis benefited more from the dual inhibition of the vascular endothelial growth factor and programmed cell death 1 or programmed cell death ligand 1 pathways.